Navigation Links
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Date:11/2/2009

BOTHELL, WA and VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon to provide a business update and discuss the third quarter results.

A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-466-4520 (U.S. & Canada) or 719-457-2729 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in phase 1 clinical development; SN2310 has completed a phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/18/2014)... Austin, TX (PRWEB) September 18, 2014 ... of integrated urological and interventional radiology products and ... (also known as cryotherapy and cryoablation) versus external ... Mid-Atlantic Section of the American Urological Association (MAAUA) ... , "Comparing Relative Effectiveness of Cryosurgery and ...
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... OpenClinica at the 2009 ACRP Global Conference & Exhibition, April 24-28 ... ... Denver, CO (PRWEB) April 23, 2009 -- The 2009 Global ... will include presentations and exhibitions on OpenClinica, the world,s leading open ...
... SEATTLE, April 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... preclinical data regarding its SCORPION(TM) multispecific therapeutic technology ... Association of Cancer Research (AACR) in Denver. The ... of the bispecific CD79BxDR SCORPION molecule, its differentiation ...
... to sustainabilityLAS VEGAS, April 22 Bayer CropScience ... tomorrow today through its sustainability efforts. Today, John ... CropScience, presented Tom Lovelace, United Fresh Produce Association ... the next four years to create the Center ...
Cached Biology Technology:Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability 2Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability 3Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability 4
(Date:9/18/2014)... cheerful, happy-go-lucky characters, so you might expect that most ... In fact some dogs are distinctly more pessimistic than ... , "This research is exciting because it measures positive ... It offers researchers and dog owners an insight into ... Dr Melissa Starling, from the Faculty of Veterinary Science. ...
(Date:9/18/2014)... Sydney, September 18, 2014 Elsevier, a world-leading ... and services, and the Australasian Research Management Society ... young scientists at the 5th Scopus Young Researcher ... held earlier today at the National Convention Centre ... conference, was attended by guests representing Australia,s and ...
(Date:9/18/2014)... found clownfish larvae can swim up to 400 kilometres in ... cope with environmental change. , Clownfish spend their entire adult ... babies they must wander the open ocean, says study co-author, ... Coral Reef Studies (Coral CoE) at James Cook University. , ... now we,ve been given a rare glimpse into how far ...
Breaking Biology News(10 mins):Dogs can be pessimists too 2Dogs can be pessimists too 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Nemo's epic journey to find a new home 2
... While Americans generally consume enough protein, they tend ... at lunch, and the largest amount at dinner. ... scientific meeting in Atlanta shows that eating high protein ... compared with a low-protein breakfast (pancakes and syrup) or ...
... their planners or their iPhones keep them organized, when proteins ... more to do with it. New research from postdoctoral fellow ... published in Proceedings of the National Academy of Sciences ... protein keeps people organized on a basic level by promoting ...
... 2013 The world should aim to have vaccines which ... eliminating malaria, licensed by 2030, according to the updated 2013 ... in addition to the original 2006 Roadmap,s goal of having ... form of the disease, for children under 5 years of ...
Cached Biology News:New malaria vaccines roadmap targets next generation products by 2030 2
... Corning CellBIND surface is produced by a ... hydrophilic surface giving more consistent, even cell ... enhances cell attachment and growth uunder difficult ... • CellBIND may provide a more ecominic ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
Biology Products: